05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and medicinal preparations for use as a soft tissue filler or for wrinkle correction Medical devices, namely, implants in gel form sold individually or in a set for use in filling lines, wrinkles, scars, lips, for tightening the face and body and for rejuvenating the skin; syringes for medical purposes; injection syringes; injection devices for pharmaceutical products; medical devices, namely, implants for use in the field of skin care and skin treatments
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and medicinal preparations for use as a soft
tissue filler or for wrinkle correction. Medical devices, namely, implants in gel form sold
individually or in a set for use in filling lines, wrinkles,
scars, lips, for tightening the face and body and for
rejuvenating the skin; syringes for medical purposes;
injection syringes; injection devices for pharmaceutical
products; medical devices, namely, implants for use in the
field of skin care and skin treatments.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and medicinal preparations for use as a soft
tissue filler or for wrinkle correction. Medical devices, namely, implants in gel form sold
individually or in a set for use in filling lines, wrinkles,
scars, lips, for tightening the face and body and for
rejuvenating the skin; syringes for medical purposes;
injection syringes; injection devices for pharmaceutical
products; medical devices, namely, implants for use in the
field of skin care and skin treatments.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Pharmaceutical and medicinal preparations for use in dermatology, namely for filling lines, wrinkles, scars, and lips, for tightening the face and body, and for rejuvenating the skin; Pharmaceutical and medicinal preparations for use in dermatology, namely for filling lines, wrinkles, scars, and lips, for tightening the face and body, and for rejuvenating the skin
(2) Medical devices, namely, implants in gel form sold individually or in a set pre-filled with a dermatological preparation each for use in filling lines, wrinkles, scars, lips, for tightening the face and body and for rejuvenating the skin; syringes for medical purposes; injection syringes; injection devices for pharmaceutical products, namely syringes; medical devices, namely, implants for the treatment of dermatological diseases and disorders namely fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, and eczema
6.
TREATMENT OF MODERATE TO VERY SEVERE GLABELLAR LINES AND LATERAL CANTHAL LINES
Disclosed herein are methods of treatment of moderate to severe and very severe glabellar lines and lateral canthal lines using liquid botulinum neurotoxin compositions. Also disclosed are liquid compositions of botulinum neurotoxin.
Disclosed herein are methods of treatment of moderate to severe and very severe glabellar lines and lateral canthal lines using liquid botulinum neurotoxin compositions. Also disclosed are liquid compositions of botulinum neurotoxin.
Described herein are compositions comprising (i) Isopropylcarbonate Benzoyl Peroxide, (ii) an opacifier, and (iii) and a preserving agent that have good physical, chemical and microbiological stability and corresponding methods of use.
A pharmaceutical packaging system includes a substrate having a first surface, a first hollow cavity accessible through a first opening in the first surface, and a second hollow cavity accessible through a second opening in the first surface. The first and second hollow cavities are spaced apart and isolated from one another on the substrate. A cover is attached to at least a first portion of the first surface of the substrate surrounding the first opening and a second portion of the first surface of the substrate surrounding the second opening so as to provide a first seal for the first hollow cavity and a second seal for the second hollow cavity. At least one orally-administered medicament is contained within one of the first and second hollow cavities, and a first topically-applied medicament is contained within the other of the first and second hollow cavities.
B65B 11/52 - Enclosing articles, or quantities of material, by disposing contents between two sheets, e.g. pocketed sheets, and securing their opposed free margins one sheet being rendered plastic, e.g. by heating, and forced by fluid pressure, e.g. vacuum, into engagement with the other sheet and contents, e.g. skin-packaging
B65D 75/36 - Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages
B65B 31/02 - Filling, closing, or filling and closing, containers in chambers maintained under vacuum or superatmospheric pressure or containing a special atmosphere, e.g. of inert gas
10.
TREATMENT OF SKIN LESIONS AND PRURITUS IN PRURIGO NODULARIS PATIENTS
Disclosed herein are methods for selectively treating pruritus in a subject having chronic prurigo (CP), including prurigo nodularis (PN), pharmaceutical compositions for use in the treatment of pruritus in a subject having CP or PN, uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of pruritus in a subject having CP or PN.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure relates to compositions comprising hydrogels and solid particles and their use. More specifically, the proposed technique relates to methods for manufacturing of a composition comprising solid particles encapsulated within crosslinked polysaccharide molecules forming hydrogel particles, the method comprising mixing water-soluble polysaccharide molecules comprising one or more carboxyl groups, water insoluble solid particles, a di- or multinucleophilic functional crosslinker, and a coupling agent, in a water suspension at pH between 5 and 9, to form a composition comprising a hydrogel of crosslinked polysaccharide molecules encapsulating the solid particles. The disclosure comprises the composition, methods for producing the composition and use of the composition as a dermal filler.
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Pharmaceutical and medicinal preparations for use in dermatology, namely filling lines, wrinkles, scars, and lips, for tightening the face and body, and for rejuvenating the skin
(2) Medical devices, sold individually or in a set, namely implants in gel form and syringes pre-filled with a dermatological preparation each for filling lines, wrinkles, scars, and lips, tightening the face and body, and for rejuvenating the skin
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Pharmaceutical and medicinal preparations for use in dermatology, namely filling lines, wrinkles, scars, and lips, for tightening the face and body, and for rejuvenating the skin
(2) Medical devices, sold individually or in a set, namely implants in gel form and syringes pre-filled with a dermatological preparation each for filling lines, wrinkles, scars, and lips, tightening the face and body, and for rejuvenating the skin
16.
POST-CROSSLINKING PARTIAL DEGRADATION OF AMIDE CROSSLINKED HYDROGELS
The present invention relates to an injection device comprising a drive mechanism (10), the drive mechanism (10) comprising a drive rod (11) being axially moveable, a plunger rod (12) being axially moveable, and a gear assembly (20). The gear assembly (20) is arranged such that an axial movement of the drive rod (11) generates an axial movement of the plunger rod (12). This allows for a force transmission between the drive rod (11) and the plunger rod (12), facilitating the expelling of viscous substances from the injection device.
Disclosed herein are methods for selectively treating atopic dermatitis (AD) in a subject having skin excoriations, pharmaceutical compositions for use in the treatment of atopic dermatitis in a subject having skin excoriations, uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of atopic dermatitis in a subject having skin excoriations, and methods of identifying a subject having atopic dermatitis that is likely to respond to nemolizumab treatment or an equivalent thereof.
The present invention provides an injectable filler composition comprising a cross- linked hyaluronic acid and a therapeutically effective amount of bupivacaine, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein the composition has a pH of 7.1 or lower and comprises phosphate buffer at concentration of between 0.5 and 5 mM. The composition can be manufactured by (a) preparing an aqueous mixture of cross-linked hyaluronic acid and a therapeutically effective amount of bupivacaine, or a pharmaceutically acceptable salt, ester or prodrug thereof; (b) adjusting the pH of the aqueous mixture to 7.1 or lower; and (c) autoclaving the mixture to obtain an injectable filler composition.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
The present invention provides a method of producing an injectable gel product, comprising the steps of a) cross-linking a first glycosaminoglycan (GAG) with a first crosslinking agent to produce a gel, wherein the charging ratio of crosslinking agent to disaccharide unit is below 0.15; b) preparing particles of the gel from step a); c) mixing the glycosaminoglycan (GAG) gel particles of step b) with a second glycosaminoglycan (GAG) to provide a mixture; d) cross-linking the mixture of step c) with a second crosslinking agent to obtain cross-linking between the glycosaminoglycans (GAGs) of the second, outer phase, thereby providing a gel having a first, inner phase of the cross-linked glycosaminoglycan (GAG) gel particles, embedded in a gel of the second, outer phase comprising the second glycosaminoglycan (GAG), and e) preparing injectable particles of the gel from step d), each such particle containing a plurality of the cross-linked GAG gel particles of the first, inner phase. The present invention further provides an injectable gel product, an aqueous composition, and a pre-filled syringe.
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
An exchangeable cartridge containing a liquid composition, said cartridge (3) comprising a container (4), and a plunger (10) slidably arranged within the container, wherein the plunger is connectable with a plunger rod (9), wherein the container is arranged to receive the plunger rod from its rear end, wherein the plunger comprises a rod connector (12) connectable with a front end portion (13) of the plunger rod, the rod connector having a base portion (24), an outer wall section (15) extending rearwards from the base portion, an inner wall section (16) extending rearwards from the base portion, and a rod stop portion (17) encircled by the inner wall section, wherein the inner wall section comprises several tongues (22) protruding rearwards from the base portion, and defining an entrance opening (18) for the plunger rod, wherein the inner wall section is arranged to receive a front portion (13) of the plunger rod through the entrance opening, and wherein the tongues are provided with retaining portions, which are arranged to retain the front end portion during retraction of the plunger rod within the housing.
The present invention relates to a method of preparing a sterilized injectable hydrogel composition, comprising the steps: a) providing an amide crosslinked glycosaminoglycan, b) swelling the amide crosslinked glycosaminoglycan in a solution comprising a divalent cation to form a hydrogel composition, and c) sterilizing the hydrogel composition by autoclaving to form a sterilized injectable hydrogel composition, and to sterilized injectable hydrogel compositions obtainable by such method.
A method of preparing a hydrogel product comprising crosslinked glycosaminoglycan molecules, said method comprising: i) providing a crosslinked glycosaminoglycan, wherein said glycosaminoglycan is at least partially N-deacetylated such that the crosslinked glycosaminoglycan comprises free amine groups; and ii) covalently grafting a reactive side-chain to the free amine groups of the crosslinked glycosaminoglycan, wherein the reactive side-chain comprises a functional group capable of forming a covalent bond to the free amine groups, and a side-chain moiety selected from the group consisting of a hydrophobic moiety, a charged moiety, and a peptide moiety. A hydrogel product comprising a crosslinked glycosaminoglycan, wherein at least some of the acetyl groups of the N-acetyl glucosamine (GlcNAc) repeating units of the glycosaminoglycan have been substituted by a side chain comprising a side-chain moiety selected from the group consisting of a hydrophobic moiety, a charged moiety, and a peptide moiety.
A method of preparing a sterilized injectable hydrogel composition, comprising the steps: a) providing a covalently crosslinked glycosaminoglycan, b) swelling the covalently crosslinked glycosaminoglycan in a solution comprising Bis-Tris buffer, and c) sterilizing the hydrogel composition by autoclaving to form a sterilized injectable hydrogel composition. A sterilized injectable hydrogel composition comprising: i) a covalently crosslinked glycosaminoglycan, and ii) Bis-Tris buffer.
C07C 215/12 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A method of preparing a hydrogel product comprising crosslinked glycosaminoglycan molecules, said method comprising: (i) providing an amide crosslinked glycosaminoglycan; (ii) activating carboxyl groups on the glycosaminoglycan with a coupling agent to form an activated glycosaminoglycan; (iii) grafting an aminodextran to the activated glycosaminoglycan via the activated carboxyl groups, and a hydrogel product comprising an amide crosslinked glycosaminoglycan, grafted with a dextran, wherein said dextran is covalently bound to the glycosaminoglycan by amide bonds.
A method of preparing a hydrogel product comprising crosslinked glycosaminoglycan molecules, said method comprising: i) providing a crosslinked glycosaminoglycan, wherein said glycosaminoglycan is at least partially N-deacetylated such that the crosslinked glycosaminoglycan comprises free amine groups; and ii) covalently grafting an aldehyde or hemiacetal functionalized dextran or cyclodextrin to the free amine groups of the crosslinked glycosaminoglycan.
A method of preparing a hydrogel product comprising crosslinked glycosaminoglycan molecules, comprising the steps of: (a) providing a mixed solution of glycosaminoglycan molecules, a di- or multinucleophilic functional crosslinker, and a mononucleophilic functional graft chain; (b) activating carboxyl groups on the glycosaminoglycan molecules with a coupling agent to form activated glycosaminoglycan molecules; and (c) simultaneously crosslinking the activated glycosaminoglycan molecules and grafting the graft chain to the activated glycosaminoglycan molecules by reacting the nucleophiles with the activated carboxyl groups.
A medical multiple skin biopsy device for removal of skin tissue comprising a body having a proximal end and a distal end, the distal end being arranged to engage with the skin surface; a tubular outer core element arranged inside the body and comprising a cutting portion at a distal end thereof; a tubular inner core element arranged inside the outer core element and comprising a cutting portion at a distal end thereof; and an operation unit connected with the outer and inner core elements. A space is defined between at least a distal end portion of an outer wall of the inner core element and at least a distal end portion of an inner wall of the outer core element. The outer and inner core elements are axially moveable between a retracted position, and an extended position in which the cutting portions of the core elements protrude from the body. The operation unit is arranged for moving the core elements between the retracted and extended positions, whereby the medical skin biopsy device is arranged for cutting at least two skin tissue samples in one operation.
A conical needle (210) includes a hollow needle body (220) which has a distal end and a proximal end. The needle body has a substantially consistent cross-sectional diameter along the entire length of a central longitudinal axis of the needle body between the proximal end and the distal end of the needle body. The interior of the needle body defines a fluid pathway (282) extending along the longitudinal axis. A conical portion (270) is located at the distal end of the needle body. The conical portion has a sidewall (272), a distal end, and a proximal end. The conical portion forms a sharp tip (250) located at the distal end of the conical portion. A lateral opening (240) is located fully within the sidewall of the conical portion. The lateral opening is in fluid communication with the fluid pathway.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Cosmetic preparations; personal care products, namely, non-medicated skin creams, facial moisturizers, skin cleansers, age retardant gels and beauty lotions; non-medicated skin cream for general skin irritations; cosmetic sunscreen preparations and sun block Pharmaceutical preparations and substances for use in dermatology; Pharmaceutical preparations and substances for the treatment of glabellar lines, facial wrinkles, asymmetries, defects and related skin disorders; biological dermal implants, namely, injectable visco-supplementation solutions for filling wrinkles; injectable dermal fillers consisting of artificial materials, namely, visco-supplementation solutions for filling wrinkles and skin volume Medical devices, namely, phototherapeutic apparatus Medical services; health counseling; skin health care information; beauty care information
31.
SYSTEMS AND METHODS FOR ITCH MONITORING AND MEASUREMENT
A system for monitoring and measuring itch of a patient includes a wearable device including an actigraph sensor; and a controller electrically connected to the wearable device and including a processor and a memory. The wearable device is configured to measure, via the actigraph sensor, a movement of the patient; and send data indicative of the measured movement of the patient to the controller. The controller is configured to receive, via the processor, the data indicative of the measured movement; and determine, via the processor, a scratching movement of the patient based on the data indicative of the measured movement.
The invention relates to a micro- or nanoparticular multilamellar vesicle constituted of concentric membranes comprising at least one non-ionic surfactant of the sucrose ester type comprising at least one chain arising from a linear or branched, saturated or unsaturated, optionally mono- or polyhydroxylated C12 to C22 fatty acid, which vesicle comprises at least a hyaluronic acid (HA), wherein the hyaluronic acid is a crosslinked hyaluronic acid. The invention also relates to a method of manufacture of such vesicle, compositions comprising such vesicle and their uses.
The present invention provides a method for evaluating the biointegration characteristics of an injectable gel comprising the steps of a) injecting the gel intradermally in a tissue sample; b) sectioning said tissue sample to provide at least one cross-sectional sample suitable for microscopic analysis; c) staining said at least one cross-sectional sample; d) determining a level of integration of said gel into said tissue based on microscopic analysis of at least one stained cross-sectional sample; and e) determining a biointegration value for said injectable gel that is proportional to the level of integration determined in step d).
The invention relates to a micro- or nanoparticular vesicle comprising at least a crosslinked hyaluronic acid (HA), wherein the crosslinked hyaluronic acid is crosslinked by a chemical crosslinking agent, and wherein the degree of modification of said crosslinked hyaluronic acid with said chemical crosslinking agent is less than 1.9 mole %. The invention also relates to a method of manufacturing such vesicles, compositions comprising such vesicles and their uses.
The invention relates to a composition comprising, in a physiologically acceptable medium, a crosslinked hyaluronic acid (HA), having a degree of modification less than 1.9 mole %; a HA with a molecular weight of about 50 kDa or less; and/or an agent stimulating endogenous HA synthesis. The invention also relates to a cosmetic use of such composition in skin care and/or anti-ageing treatment.
The invention relates to a capsule (1) comprising a cup composed of a least one lateral wall (2) and a lower wall (4); and a cover (3), for use thereof in a device for producing and distributing compositions, the capsule (1) comprising at least one ingredient for extemporaneously producing a personalised cosmetic and/or pharmaceutical composition by mixing said ingredient with at least one physiologically acceptable carrier, wherein said ingredient is a probiotic microorganism that improves the balance of the skin microbiome.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
B65D 81/00 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
The present invention provides a process for evaluating rheological characteristics of an injectable gel comprising measuring the flexibility, wherein the flexibility is evaluated by measuring the strain at the crossover point of the amplitude sweep. As an example, the process may comprise subjecting an injectable gel to oscillating mechanical stresses to determine G' and G" as a function of strain (γ) in an amplitude sweep, determining the crossover point as the point at which G' and G" have the same value, determining the strain Ycrass at the crossover point, and determining the flexibility of the injectable gel as Ycrass or proportional to Ycross. The present invention further provides a method of comparison of dermal fillers by measuring their flexibility and a method of evaluation of dermal filler behavior in human skin by measuring the flexibility according to the previous claims.
G01N 11/16 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties by moving a body within the material by measuring damping effect upon oscillatory body
The invention relates to a dermatological or pharmaceutical composition comprising at least one aqueous phase, at least one fatty phase comprising one or more fatty compounds and at least one active phase comprising one or more active compounds chosen from avermectin compounds and one or more solvents and/or propenetrating agents of avermectin compounds, where the composition does not comprise gelling agent. The invention relates also to the composition for use in the treatment of rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of atopic dermatitis, and preferably for use in the treatment of rosacea. Finally, the invention relates to a method for preparing the composition.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
The invention relates to adermatological or pharmaceutical composition comprising at least one aqueous phase and at least one active phase comprising at least oneactive compound chosen from avermectin compounds and at least one solvent and/or propenetrating agent of avermectin compounds, where the composition comprises less than 3 % by weight of solidfatty substancesat room temperatureand at atmospheric pressure, relative to the total weight of the composition. The invention relates also to the composition for use in the treatment of rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of atopic dermatitis, and preferably for use in the treatment of rosacea. Finally, the invention relates to a method for preparing the composition.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
40.
COMPOSITION COMPRISING AVERMECTIN COMPOUNDS WITHOUT SOLVENTS AND PROPENETRATING AGENTS OF AVERMECTIN COMPOUNDS
The invention relates to a dermatological or pharmaceutical composition comprising at least one aqueous phase and at least one fatty phase comprising one or more fatty compounds different from solvents and/or propenetrating agents of avermectin compounds and at least one active compound chosen from avermectin compounds, where the composition comprises neither solvents nor propenetrating agents of avermectin compounds. The invention relates also to the composition for use in the treatment of rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of a topic dermatitis, and preferably for use in the treatment of rosacea. Finally, the invention relates to a method for preparing the composition.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
The present invention relates to a pharmaceutical composition comprising a compound of the avermectin family, preferably ivermectin, in a pharmaceutically acceptable carrier, for use in the treatment and/or prevention of hand eczema.
The present invention relates to a method of preparing a sterilized injectable hydrogel composition, comprising the steps: a) covalently crosslinking a glycosaminoglycan using a bi- or polyfunctional crosslinking agent to form a covalently crosslinked glycosaminoglycan, b) swelling the covalently crosslinked glycosaminoglycan in a solution comprising a divalent zinc cation to form a hydrogel composition, and c) sterilizing the hydrogel composition by autoclaving to form a sterilized injectable hydrogel composition, and to sterilized injectable hydrogel compositions obtainable by such method.
The present invention relates to a composition comprising a pharmaceutically acceptable carrier, at least one compound of the avermectin family, and at least one non-steroidal anti-inflammatory compound. The present invention further provides such composition for use in the treatment and/or the prevention of rosacea.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A hyaluronic acid product is comprising a cross-linked hyaluronic acid and one or more cyclodextrin molecules, and further comprising a guest molecule capable of forming a guest-host complex with the aminocyclodextrin molecule acting as a host, wherein the guest molecule is a retinoid, preferably adapalene, or a RAMBA. The hyaluronic acid is cross-linked by ether bonds, and the one or more cyclodextrin molecules are grafted onto the cross-linked hyaluronic acid by amide bonds, preferably using a triazine-based coupling reagent.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
a) providing a molecule comprising an amide group; b) reacting the molecule comprising an amide group with a hydroxylamine salt to cleave the amide bond of the amide group.
The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.
The present disclosure is directed a method for evaluating a sunscreen. The method comprises measuring a protective effect of a sunscreen and at least one cellular alteration caused by irradiation. The measured effects are evaluated against a control for the at least one cellular alteration caused by irradiation.
A pharmaceutical or cosmetic composition comprising an Indigo Naturalis or Indigo-producing plant extract for treating atopic dermatitis and any form of eczema, and a method of treating atopic dermatitis comprising administering a therapeutically effective amount of an Indigo Naturalis or Indigo-producing plant extract to a subject in need thereof are described.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
The present specification relates to a syringe comprising a barrel, a plunger moveably arranged within the barrel and a plunger rod for driving the plunger, and a mechanism for providing feedback to a user as the plunger rod is moved relative to the barrel for driving said plunger such that feedback is given to a user as the plunger rod is moved relative to the barrel for driving the plunger. The plunger rod is arranged to drive the plunger such that a predetermined relative movement between at least a portion of the plunger rod and the plunger is allowed. The present specification further relates to a plunger assembly wherein a predetermined relative movement between at least a portion of the plunger rod and the plunger is allowed
According to a first aspect of the invention a syringe comprising a barrel (1), a plunger (2) moveably arranged within said barrel and a plunger rod (3) for driving said plunger is provided. The syringe comprises a first engagement member (30) arranged at the plunger rod such that a longitudinal movement of the plunger rod yields a rotational movement of said first engagement member, said first engagement member comprising a grooved surface, and a second engagement member (40) arranged at the barrel to engage with said grooved surface of the first engagement member such that feedback is given to a user as the plunger rod is moved relative to the barrel for driving said plunger. Wherein, for a given distance D travelled by the plunger rod relative to the barrel, a point of the grooved surface of the first engagement member moves a distance d, wherein d≥D.
The present specification relates to a syringe comprising a barrel (1), a plunger (2) moveably arranged within said barrel, and a plunger rod (3) for driving said plunger. A first engagement member (30) is arranged at the plunger rod, such that a longitudinal movement of the plunger rod yields a rotational movement of said first engagement member. The first engagement member comprises a grooved surface. A second engagement member (40) is arranged at the barrel to engage with said grooved surface of the first engagement member, wherein the first engagement member is arranged to move relative to the second engagement member, such that feedback is given to a user as the plunger rod is moved relative to the barrel for driving said plunger. The first engagement member is arranged at said plunger rod with a predetermined play there between.
A method for cleaving amide bonds, comprising: a) providing a molecule comprising an amide group; b) reacting the molecule comprising an amide group with hydroxylamine (NH2OH) or a salt thereof to cleave the amide bond of the amide group.
A method for at least partial deacetylation of a biopolymer comprising acetyl groups, comprising: a1 ) providing a biopolymer comprising acetyl groups; a2) reacting the biopolymer comprising acetyl groups with hydroxylamine (NH2OH) or a salt thereof at a temperature of 100 °C or less for 2-200 hours to form an at least partially deacetylated biopolymer; and a3) recovering the at least partially deacetylated biopolymer.
A method of preparing a hydrogel product comprising crosslinked glycosaminoglycan molecules, said method comprising: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans comprise residual amine groups; and ii) acylating residual amine groups of the crosslinked glycosaminoglycans provided in i) to form acylated crosslinked glycosaminoglycans.
A method of preparing a hydrogel product comprising crosslinked glycosaminoglycan molecules, said method comprising: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans comprise ester crosslinks formed as byproducts during the amide crosslinking; and ii) subjecting the crosslinked glycosaminoglycans to alkaline treatment to hydrolyze ester crosslinks formed as byproducts during the amide crosslinking.
The invention relates to a hydrogel product comprising glycosaminoglycan molecules as the swellable polymer, wherein the glycosaminoglycan molecules are covalently crosslinked via crosslinks comprising a spacer group selected from the group consisting of di-, tri-, tetra-, and oligosaccharides.
The present invention relates to a combination of ivermectin and brimonidine for use in the treatment and/or the prevention of moderate to severe rosacea, preferably by topical administration of a 1% ivermectin cream and 0.33% brimonidine gel.
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
The present invention pertains to a process for preparing a stable emulsion comprising at least one avermectin. It is also directed to the emulsion thus obtained, especially for use in the treatment of dermatological disorders such as rosacea.
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
63.
A PROCESS FOR PREPARING A COMPOSITION COMPRISING A HIGH CONCENTRATION OF ONE OR MORE AVERMECTINS
The present invention pertains to a process for preparing a composition in the form of an emulsion comprising a high concentration of one or more avermectins. This process comprises partitioning said avermectin between an active phase comprising at least one glycol and the oily phase of the emulsion. This invention is also directed to the composition thus obtained, especially for use in the treatment of dermatological disorders such as rosacea.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
64.
METHOD OF IMPROVING VISUAL APPEARANCE OF NAILS AFFECTED BY ONYCHOMYCOSIS
The invention relates to method of improving visual appearance of nails affected by onychomycosis comprising the steps of: applying an antifungal nail lacquer comprising amorolfine to the affected nails; and applying, on said nails coated with said nail lacquer, a cosmetic nail varnish.
A process for manufacturing a cross-linked hyaluronic acid (HA) gel product is comprising the steps of: (a) preparing an aqueous mixture of HA and a cross-linking agent selected from multiepoxides and diepoxides; wherein the HA is dissolved in an aqueous solution containing 1-10 % (w/w) inorganic hydroxide; and wherein the dissolved HA constitutes more than 10 % (w/w) of the final mixture; and (b) subjecting the aqueous mixture to cross-linking conditions to allow the dissolved HA to react with the cross-linking agent so as to obtain a cross-linked HA gel product.
A method of reducing hair loss (alopecia) in a patient undergoing or scheduled to undergo chemotherapy is claimed. The method involves administering brimonidine or a pharmaceutically acceptable salt thereof to the site of the hair follicles.
A process of preparing a cross-linked polysaccharide product comprising hyaluronic acid and dextran, the process comprising the steps of: (a) providing a hyaluronic acid and a dextran; (b) binding the dextran to the hyaluronic acid by ether bonds using a bi-or polyfunctional cross-linking agent.
The present invention relates to a process for preparing an extract from one or more botanical raw materials, such as Indigo Naturalis and the extract itself. The present invention also relates to a composition comprising the extract, as well as the use of composition in medical or cosmetic applications.
A pharmaceutical or cosmetic composition comprising Indigo Naturalis or Indigo-producing plant extract for treating candidiasis, and a method of treating candidiasis comprising administering therapeutically effective amount of Indigo Naturalis or Indigo-producing plant extract to a subject in need thereof are described.
A pharmaceutical or cosmetic composition for use in the treatment of a nail disorder comprising an Indigo Naturalis or Indigo-producing plant extract, and a method of treating a nail disorder comprising administering a therapeutically effective amount of an Indigo Naturalis or Indigo-producing plant extract to subjects in need thereof are described.
A pharmaceutical or cosmetic composition comprising Indigo Naturalis or Indigo-producing plant extract for treating paronychia, and a method of treating paronychia comprising administering a therapeutically effective amount of Indigo Naturalis or Indigo-producing plant extract to a subject in need thereof are described.
A pharmaceutical or cosmetic composition comprising an Indigo Naturalis or Indigo-producing plant extract for treating atopic dermatitis and any form of eczema, and a method of treating atopic dermatitis comprising administering a therapeutically effective amount of an Indigo Naturalis or Indigo-producing plant extract to a subject in need thereof are described.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
74.
ANTIBACTERIAL INDIGO NATURALIS OR INDIGO-PRODUCING PLANT EXTRACT AND USE THEREOF
A pharmaceutical or cosmetic composition comprising an Indigo Naturalis or Indigo-producing plant extract, for inhibiting Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, and a method of inhibiting Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, comprising contacting an effective amount of an Indigo Naturalis or Indigo-producing plant extract to a cell in need thereof are described.
The present invention relates to a syringe (100) comprising a barrel (1), a plunger (2) moveably arranged within the barrel (1) and a plunger rod (3) for driving the plunger (2), and an engagement member (4) arranged at the barrel (1) to engage with a grooved surface (5) on the plunger rod (3). This will create feedback given to a user as the plunger rod (3) is moved relative to the barrel (1) for driving the plunger (2) within the barrel (1). The barrel (1) and the engagement member (4) are arranged relative to each other such that the engagement member (4), due to the engagement with the grooved surface (5) of the plunger rod (3), will move solely in a direction generally perpendicular to a longitudinal direction of the plunger rod (3) as the plunger rod (3) is moved relative to the barrel (1).
The present invention relates to a compound from the avermectin family for use in treating and/or preventing folliculitis caused by anti-cancer agents and more particularly by agents for targeted therapy. The compound from the avermectin family is preferably ivermectin.
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
77.
CARBOXYL CROSS-LINKED CHONDROITIN HYDROGELS AND THEIR USE FOR SOFT TISSUE APPLICATIONS
A hydrogel product is comprising a chondroitin molecule selected from the group consisting of chondroitin and chondroitin sulfate as the swellable polymer, wherein the chondroitin molecule is cross-linked into a network via its carboxyl groups. The hydrogel product can be prepared by a process comprising the steps of (a) providing chondroitin molecules; (b) activating the carboxyl groups on the chondroitin molecules with a triazine-based coupling reagent to form an activated, cross-linked chondroitin; and (c) cross-linking the activated chondroitin molecules via their carboxyl groups using a cross- linking agent. The hydrogel product is useful for treatment of soft tissue disorders.
B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons
A graft copolymer comprising: a core polymer comprising a crosslinked or non-crosslinked polysaccharide,a plurality of primary graft polymers covalently grafted to the core polymer,a plurality of secondary graft polymers covalently grafted to each primary graft polymer, an injectable dermal aesthetic formulation comprising such a graft copolymer and a method of preparing such a graft copolymer.
A hyaluronic acid product is comprising a cross-linked hyaluronic acid and one or more cyclodextrin molecules. The hyaluronic acid is cross-linked by ether bonds, and the one or more cyclodextrin molecules are grafted onto the cross-linked hyaluronic acid by amide bonds, preferably using a triazine-based coupling reagent.
The present invention relates to a compound of the avermectin family, preferably ivermectin, for use in the treatment and/or prevention of inflammatory dermatoses especially neutrophilic dermatoses. It also relates to a pharmaceutical composition comprising avermectin family compound, preferably ivermectin, with a pharmaceutical acceptable carrier to treat and/or prevent inflammatory dermatoses and especially neutrophilic dermatoses.
The present invention relates to the use of a compound of the avermectin family preferably ivermectin, in the treatment and/or prevention of inflammatory dermatoses especially neutrophilic dermatoses, in combination with at least one other active compound.
COMPOSITIONS COMPRISING A COMPOUND FROM THE FAMILY OF AVERMECTINS AND AN AGONIST COMPOUND FOR AT LEAST ONE OF THE RETINOIC ACID RECEPTORS FOR TREATING ACNE
The invention relates to one of the compositions comprising a compound of the family of avermectins, preferably ivermectin, and an agonist compound for at least one of the retinoic acid receptors, in particular used in the treatment of acne.
A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
Doxycycline formulations with a reduced food effect are disclosed. Particularly disclosed are modified release formulations which can be administered once a day and exhibit a reduced food effect. Methods of treating inflammatory conductions such as rosacea or inflammatory symptoms such as the papules and pustules of rosacea or acne vulgaris are also disclosed.
Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.
The present invention relates to a new use of a composition comprising a compound from the family of avermectins, preferably ivermectin, and doxycycline or one of the salts thereof that is pharmaceutically acceptable in the treatment and/or slowing of the appearance of symptoms of rosacea.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
Enantiomers of butanediol diglycidyl ether (BDDE)are present in an enantiomerically enriched enantioenriched mixture of BDDE stereisomers or in an enantiomerically pure BDDE. Enantiomerically enriched or pure BDDE is useful as a cross-linking agent, such as in the preparation of across-linked hyaluronic acid product.
A method of treating hand-foot syndrome (palmar-plantar erythrodysesthesia) and symptoms associated therewith in a patient undergoing or scheduled to undergo chemotherapy is claimed. The method involves topically administering a pharmaceutical composition comprising an effective amount of an alpha adrenergic receptor agonist, pharmaceutically acceptable salt thereof, or combinations thereof; and a pharmaceutically acceptable carrier to the affected areas of skin or to the hands and feet.
A hydrogel product comprising (a) one or more cyclodextrin molecules grafted to hyaluronic acid and (b) dextran, wherein the cyclodextrin-grafted hyaluronic acid is cross-linked to the dextran. The one or more cyclodextrin molecules are grafted, e.g. by amide bonds, to the hyaluronic acid prior to the cross- linking with dextran.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A hydrogel product comprising (a) a cross-linked polymer mixture consisting of dextran cross-linked to hyaluronic acid, and (b) one or more cyclodextrin molecules. The one or more cyclodextrin molecules are grafted onto the cross-linked polymer mixture, e.g. by amide bonds.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A hyaluronic acid product is comprising a cross-linked hyaluronic acid and one or more dextran molecules. The hyaluronic acid is cross-linked by ether bonds, and the one or more dextran molecules are covalently grafted to the cross-linked hyaluronic acid.
The present invention relates to a method for lubricating an injection needle when used multiple times at a single occasion to penetrate a support, the method comprising the steps of: a) depositing a layer of a lubricating composition on the support; b) penetrating multiple times the layer of the lubricating composition deposited in step a) with the injection needle, thereby providing a lubricated injection needle having a deposited layer of the lubricating composition thereon.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/42 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
92.
Methods and compositions for safe and effective treatment of erythema
Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.
An injection device for delivering a liquid composition, comprising a generally elongated housing (2), arranged to hold an exchangeable cartridge (3) containing the liquid composition. The housing comprises a drive device, and a plunger rod (5) connected with the drive device and connected to a plunger within the cartridge, when the cartridge is held at the housing, for driving the plunger within the cartridge. The plunger comprises a rod connector (7) connected with a front end portion (8) of the plunger rod. The rod connector has an entrance opening defined by wall sections of the rod connector, the width of the entrance opening being smaller than the width of the front end portion. The width of a rod portion adjacent to and rear of the front end portion at the most corresponds to the width of the entrance opening. The wall sections are resilient for enabling the front end portion to pass the entrance opening upon exerting an opening force on the wall sections. The rod connector comprises a rod stop portion, wherein there is a longitudinal play between the plunger rod on one hand and the entrance opening and the rod stop portion on the other hand, thereby enabling the front end portion to move back and forth between the entrance opening and the rod stop portion without moving the plunger.
The present invention relates to a pharmaceutical composition comprising a compound of the avermectin family, preferably ivermectin, or a compound of the milbemycin family in a pharmaceutically acceptable carrier, for use in the treatment and/or prevention of atopic dermatitis.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A method of treating atrophic cutaneous scarring in humans is claimed. The method involves the topical application of a therapeutic amount of prostaglandin F2-alpha (PGF 2α) or a PGF 2α analog directly to the area of atrophic scarring.
The present invention relates to a combination of botulinum toxin and hyaluronic acid for use in the radiation treatment of cancer. The present invention also relates to a method for treating prostate cancer in a human patient, whereby one or more tumours in the prostate are shrunk, inhibited and/or dissolved and the rectum is protected from a subsequent radiation treatment step. Furthermore, the present invention relates to one or more compounds selected from botulinum toxin, hyaluronic acid and a combination of botulinum toxin and hyaluronic acid for use in the treatment of prostate cancer in a human patient by a method whereby one or more tumours in the prostate are shrunk, inhibited and/or dissolved and the rectum is protected from a subsequent radiation treatment step.
A process for manufacturing a cross-linked hyaluronic acid (HA) containing a functionalizing group is comprising the step of reacting HA with a mixture of: (i) a first cross-linking agent selected from the group consisting of bifunctional epoxides and polyfunctional epoxides, and (ii) a functionalized agent, consisting of a functionalizing group coupled via a 1,2,3-triazole linkage to a second cross-linking agent selected from the group consisting of bifunctional epoxides and polyfunctional epoxides, to obtain a cross-linked HA containing the functionalizing group. The process provides a cross-linked hyaluronic acid (HA) containing a functionalizing group. The process utilizes a functionalized agent, consisting of a functionalizing group coupled via a 1,2,3-triazole linkage to a cross-linking agent.
A needle device including a housing. The housing includes a first housing element provided towards a proximal end of said needle device and a second housing element provided towards a distal end of said needle device. A cutting element having a sharp proximal end is arranged at a proximal end of said first housing element. A cannula having a blunt proximal end is fitted to the second housing element and an opening for the cannula is provided at the proximal end of the first housing element. The first housing element and the second housing element are moveable relative to each other between an extended position where the proximal end of the cannula does not extend beyond the proximal end of the cutting element and a compressed position where the cannula extends through the opening of the first housing element and past the proximal end of the cutting element.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/46 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for controlling depth of insertion
A61M 5/34 - Constructions for connecting the needle
99.
TREATMENT OF PAPULOPUSTULAR ROSACEA WITH IVERMECTIN
Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 9/00 - Medicinal preparations characterised by special physical form
Methods for safe and effective treatment of inflammatory lesions of rosacea in a subject are described. The methods involve once daily topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. It has been demonstrated that once daily topical treatment with ivermectin is significantly superior than twice-daily topical treatment with metronidazole in reducing inflammatory lesion counts.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 9/00 - Medicinal preparations characterised by special physical form
